Get the Stockscreener App
0.00
100.00%
-0.0002
Effector Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.0002
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-34.63M
P/E Ratio:
0.00
EPS:
-13.08
Net Cash Flow:
$-29.19M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-99.58%
1Y Performance:
-99.78%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.0002
Effector Therapeutics Inc Stock (EFTR) Company Profile
Name
Effector Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare EFTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EFTR
Effector Therapeutics Inc
|
0.00 | 0 | 0 | -34.63M | -29.19M | -13.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Effector Therapeutics Inc Stock (EFTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-25-22 | Downgrade | Stifel | Buy → Hold |
| Nov-09-21 | Upgrade | Stifel | Hold → Buy |
| Oct-12-21 | Initiated | Credit Suisse | Outperform |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Sep-21-21 | Initiated | JMP Securities | Mkt Outperform |
| Sep-20-21 | Initiated | Stifel | Hold |
| Sep-13-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Effector Therapeutics Inc Stock (EFTR) Latest News
Christopher B. “Chris” Ehrlich, MBA (D’92) – Office of the Dean - Geisel School of Medicine at Dartmouth
TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care - CancerNetwork
PD-1 and PD-L1 Inhibitors Market Expands Rapidly Amid Rising Cancer Burden and Immunotherapy Adoption - openPR.com
Dania Therapeutics identifies new WNK1 inhibitors - BioWorld MedTech
eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer - PNAS
PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech - The Globe and Mail
eFFECTOR Therapeutics Faced Investigation Over Non-Compliance with Nasdaq and Delisting - TradingView
Fate Therapeutics Announces Phase 1 Data Presentation of - GlobeNewswire
RNA Targeted Therapeutics Market to See Booming Growth - openPR.com
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity - The Globe and Mail
Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com
Small-molecule RNA therapeutics to target prostate cancer - ScienceDirect.com
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting - Barchart.com
Tech-Enabled, Human-Centered: TELUS Digital and Ryan Strategic Advisory Reveal New Trust, Safety & Security Priorities for 2025 - The Globe and Mail
PD-1 and PD-L1 Inhibitors Market Report- Expansive Coverage on the Profit Sources - openPR.com
The Chlamydia effector Dre1 binds dynactin to reposition host organelles during infection - ScienceDirect.com
PD-L1 Non-small Cell Lung Cancer Treatment Market Size in 7MM - openPR.com
Global Equity Markets Slide on US Tariff Concerns - The Globe and Mail
Marjorie Taylor Greene Is Buying Up Beaten-Down Tesla Stock. Should You? - The Globe and Mail
Press Release Service: Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference - CRISPR Medicine News
News: CMN Weekly (28 February 2025)Your Weekly CRISPR Medicine News - CRISPR Medicine News
Your Ford Stock Dividend Could Be at Risk If Trump Goes Ahead with Tariffs - The Globe and Mail
Map Kinase Interacting Serine Protein Kinase 1 Market Enabling Agile and Scalable Business Models in the Digital Age - ExpressVartha
Best Statistical RNA Targeted Therapeutics Market Growth Set - openPR
eFFECTOR Therapeutics (EFTR) Projected to Post Earnings on Friday - Defense World
Atomwise Appoints Steve Worland, Ph.D. as Chief Executive Officer - Business Wire
Sarah Larson, MD, on Evaluating Lyell’s CAR-T IMPT-314 in LBCL - CGTLive®
Anakinra Used in a Patient with Diffuse Large B-Cell Lymphoma and Steroid-Refractory Immune Effector Cell–Associated Neurotoxicity Syndrome: Case Report - Journal of Hematology Oncology Pharmacy
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Structure Therapeutics selects lead oral DACRA for obesity - BioWorld MedTech
The Effector Functions of AntibodiesDaëron2024Immunological Reviews - Wiley Online Library
CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO - GlobeNewswire
BioGene Therapeutics Announces Appointment of Dr. Brian Gallagher, Jr. to Corporate Advisory Board - Newsfile
The 2024 Biotech Graveyard - Fierce Biotech
Non-COVID mRNA Vaccine and Therapeutics Market Expected to Reach $1,684.80 Million by 2031 - WhaTech
mRNA Treatment Market Exclusive Report 2024-2031 - InsightAce Analytic
Rahul Banerjee: Multicenter description of immune effector cell-associated enterocolitis as a novel toxicity of CAR T-cell therapy in multiple myeloma - Oncodaily
Targeted recruitment of immune effector cells for rapid eradication of influenza virus infections - PNAS
Keto diet plus experimental drug may shrink pancreatic tumors - Healio
Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer - PR Newswire
EFFECTOR Therapeutics to Participate in Upcoming Investor Conference - MarketScreener
A Ketogenic Diet Could Improve the Response to Pancreatic Cancer Therapy - Cancer Health
FORE Biotherapeutics Names Michael Byrnes as Chief Financial Officer - Business Wire
Policy and perspective on outpatient programs for autologous hematopoietic cell transplantation and immune-effector cell therapy administration - Frontiers
3 Publicly Traded Companies Filing for Bankruptcy as July Kicks Off - Yahoo Finance
Two healthcare SPACs go public, with several more on the hunt for deals - Endpoints News
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95 - GlobeNewswire
StockWatch: Layoffs, ARK Selloff Sink Ginkgo Bioworks - Genetic Engineering and Biotechnology News
Calif. biotech company that raised $325 million shuts down, lays off all workers - SFGATE
eFFECTOR Therapeutics to wind down operations and delist from Nasdaq - Investing.com
Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities - American Heart Association Journals
Effector Therapeutics Inc Stock (EFTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Cap:
|
Volume (24h):